ArticleBMC surgery2025
Comparison of the efficacy between unilateral biportal endoscopic transforaminal lumbar interbody fusion (UBE-TLIF) and microendoscopic discectomy (MED)-assisted minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) in the treatment of mild single-level lumbar spondylolisthesis.
Article in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative analysis of unilateral biportal endoscopy and minimally invasive transforaminal lumbar interbody fusion in treating lumbar spinal brucellosis.Frontiers in surgery · 2026Article
- Comparative efficacy of unilateral biportal endoscopy versus endoscopic foraminoplasty decompression for single-level lumbar spinal stenosis: a retrospective cohort study.Frontiers in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy of Unilateral Biportal Endoscopic Transforaminal Lumbar Interbody Fusion (UBE-TLIF) versus Microendoscopic Discectomy (MED)-assisted Minimally Invasive Transforaminal Lumbar Interbody Fusion (MIS-TLIF) in the treatment of mild single-level lumbar spondylolisthesis (LSS).
methodsClinical data from 120 LSS patients treated with UBE-TLIF (n=66) or MIS-TLIF (n=54) in our hospital’s Department of Spinal Surgery (January 2021–December 2023) were retrospectively analyzed. Intraoperative (operative time, blood loss), postoperative (time to ambulation, hospital stay), and radiographic parameters (lumbar lordosis, Cobb angle), as well as clinical outcomes (Visual Analog Scale [VAS] for back/leg pain, Oswestry Disability Index [ODI]) and Complication rates, were compared between groups.
resultsCompared with the MIS-TLIF group, the UBE-TLIF group exhibited significantly longer operative time but reduced intraoperative blood loss and shorter hospital stays (P<0.001). No significant differences were observed in preoperative or postoperative VAS and ODI scores between groups (P>0.05). Both groups demonstrated significant improvements in lumbar lordosis and Cobb angle at final follow-up (P<0.05), with no intergroup differences in the magnitude of improvement (P>0.05). Fusion rates and complication rates were comparable (P>0.05).
conclusionBoth UBE-TLIF and MED-assisted MIS-TLIF achieved satisfactory short-term outcomes for mild LSS with comparable safety profiles. Despite longer operative duration, UBE-TLIF offers advantages in reduced perioperative bleeding, shorter hospitalization, and faster early recovery without increasing complication risks compared to MIS-TLIF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.